SCHEMBL1960357

SCHEMBL1960357

CCc1nc2ccn(Cc3ccc(Br)cc3)cc-2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP19A1 P11511 1/20 0.43
GALR3 O60755 1/20 0.35
NR2F2 P24468 1/20 0.35
EGFR P00533 1/20 0.34
MET P08581 1/20 0.34
FLT1 P17948 1/20 0.33
KDR P35968 1/20 0.33
LMNA P02545 2/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 3/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TYMS P04818 1/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961885 0.82 CYP11B1 (0.40) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1959834 0.81 CYP11B1 (0.39) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1958857 0.79 AHR (0.42) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1962391 0.79 CYP11B1 (0.38) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1959746 0.79 HMOX1 (0.39) CYP11B1CYP11B2CYP19A1GALR3FLT1
SCHEMBL1962576 0.78 NR1H3 (0.47) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1959223 0.78 CYP11B1 (0.42) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1962300 0.78 NPC1 (0.41) CYP11B1CYP11B2CYP19A1FLT1KDR
SCHEMBL1958370 0.78 RAB9A (0.38) CYP11B1CYP11B2CYP19A1GALR3NR2F2
SCHEMBL1961421 0.77 CYP11B1 (0.48) CYP11B1CYP11B2CYP19A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2332938-B1 Viral inhibitors LEUVEN K U RES & DEV (BE) 2014-10-01 EP disclosed
US-8779141-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2014-07-15 US disclosed
EP-1521754-B1 VIRAL INHIBITORS LEUVEN K U RES & DEV (BE) 2011-08-31 EP disclosed
EP-2332938-A1 Viral inhibitors K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2011-06-15 EP disclosed
US-7737162-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2010-06-15 US disclosed
US-20100004281-A1 VIRAL INHIBITORS GILEAD SCIENCES, INC. 2010-01-07 US disclosed
US-20050239821-A1 Viral inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2005-10-27 US disclosed
EP-1521754-A2 VIRAL INHIBITORS K.U.Leuven Research & Development (BE) 2005-04-13 EP disclosed
WO-2004005286-A2 VIRAL INHIBITORS K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004281-A1 VIRAL INHIBITORS ZC3HAV1, MAVS, HAVCR2 CYP11B1 1458/4885CYP11B2 1903/4885CYP19A1 3722/4885
US-20050239821-A1 Viral inhibitors ZC3HAV1, ZC3HAV1L, ACE CYP11B1 783/4885CYP11B2 1113/4885CYP19A1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.